Multidrug-Resistant Acinetobacter baumannii May Cause Patients to Develop Polymicrobial Bloodstream Infection
Table 3
Comparison of the microbiological characteristics with monomicrobial AB-BSI and polymicrobial AB-BSI.
Total (n = 204)
Monomicrobial AB-BSI (n = 165)
Polymicrobial AB-BSI (n = 39)
value
Source of BSIs
Pneumonia
63 (30.9%)
56 (33.9%)
7 (17.9%)
0.052
Skin and soft tissue infection
42 (20.6%)
27 (16.4%)
15 (38.5%)
Central venous catheter
30 (14.7%)
27 (16.4%)
3 (7.7%)
0.169
Intra-abdominal
44 (21.6%)
36 (21.8%)
8 (20.5%)
0.859
Primary BSI
21 (10.3%)
16 (9.7%)
5 (12.8%)
0.564
Bone and joint
1 (0.5%)
1 (0.6%)
0 (0%)
0.626
Urinary tract infection
1 (1.0%)
1 (0.6%)
1 (2.6%)
0.264
Antibiotic resistancea
Cefoperazone/Sulbactam (127 vs 34)b
39 (24.2%)
32 (25.2%)
7 (20.6%)
0.557
Ceftazidime (162 vs. 37)b
27 (13.6%)
20 (12.3%)
7 (18.9%)
0.292
Meropenem (163 vs. 36)b
124 (62.3%)
105 (64.4%)
19 (52.8%)
0.192
Imipenem (164 vs. 39)b
120 (59.9%)
90 (54.9%)
30 (76.9%)
Ceftriaxone (120 vs. 32)b
113 (74.3%)
85 (70.8%)
28 (87.5%)
0.055
Cefepime (163 vs. 39)b
108 (53.5%)
79 (48.5%)
29 (74.4%)
Tigecycline (162 vs. 37)b
6 (3.0%)
5 (3.1%)
1 (2.7%)
0.902
Tobramycin (162 vs. 36)b
84 (42.4%)
63 (39.8%)
21 (58.3%)
Amikacin (107 vs. 27)b
32 (23.9%)
26 (24.3%)
6 (22.2%)
0.821
Gentamicin (116 vs. 29)b
79 (54.5%)
59 (50.9%)
20 (69.0%)
0.080
Piperacillin/Tazobactam (119 vs. 31)b
93 (62%)
67 (56.3%)
26 (83.9%)
Levofloxacin (165 vs. 39)b
68 (33.3%)
50 (30.3%)
18 (46.2%)
0.059
Ciprofloxacin (161 vs. 36)b
112 (56.9%)
85 (52.8%)
27 (75%)
Doxycycline (32 vs. 5)b
14 (37.8%)
12 (37.5%)
2 (40%)
0.915
Minocycline (116 vs. 31)b
124 (84.4%)
100 (86.2%)
24 (77.4%)
0.232
Ampicillin/Sulbactam (80 vs. 20)b
59 (59%)
51 (63.7%)
8 (40%)
0.053
MDR
160 ( 78.4%)
125 (75.8%)
35 (89.7%)
0.056
aNot all agents listed tested in all isolates. bThe numbers in parentheses represent the total numbers of Acinetobacter Baumannii isolates that performed the susceptibility test. Abbreviations: AB-BSI: Acinetobacter Baumannii bloodstream infection; BSI: bloodstream infection; MDR: multidrug resistance. Significant.
